The likelihood of a short-covering move along with addition of fresh position exists only if Nifty breaches 11,200
Domestic players will be free to price it; Dutch firm Mylan also to make the drug in India; no royalty for Gilead as yet
The company did not provide any details about the issues raised by the USFDA in its warning letter
Improvement in margins and lower debt should help increase net profits
Jubilant Life Sciences has a total of 84 ANDAs for oral solids filed in the US